Table 1 Demographic characteristics and HPV positivity at baseline in the DoRIS trial. Data are median (IQR) or n (%)
From: Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial
1 dose 2-valent (n = 155) | 2 doses 2-valent (n = 155) | 3 doses 2-valent (n = 155) | 1 dose 9-valent (n = 155) | 2 doses 9-valent (n = 155) | 3 doses 9-valent (n = 155) | Total (n = 930) | |
|---|---|---|---|---|---|---|---|
Age (years) | 10 (9–12) | 11 (10–12) | 10 (9–12) | 10 (9–12) | 11 (10–13) | 11 (9–13) | 10 (9–12) |
Age group | |||||||
9–10 years | 85 (54·8%) | 74 (47·7%) | 85 (54·8%) | 88 (56·8%) | 70 (45·2%) | 73 (47·1%) | 475 (51·1%) |
11–12 years | 39 (25·2%) | 45 (29·0%) | 36 (23·2%) | 41 (26·5%) | 45 (29·0%) | 41 (26·5%) | 247 (26·6%) |
13–14 years | 31 (20·0%) | 36 (23·2%) | 34 (21·9%) | 26 (16·8%) | 40 (25·8%) | 41 (26·5%) | 208 (22·4%) |
HPV 16 DNA positive | 0 | 0 | 1 (0·6%) | 1 (0·6%) | 0 | 1 (0·6%) | 3 (0·3%) |
HPV 18 DNA positive | 0 | 0 | 2 (1·3%) | 1 (0·6%) | 0 | 0 | 3 (0·3%) |
High-risk HPV genotype DNA | 0 | 2 (1·3%) | 4 (2·6%) | 6 (3·9%) | 2 (1·3%) | 3 (1·9%) | 17 (1·8%) |
HPV genotype DNA | 0 | 2 (1·3%) | 4 (2·6%) | 7 (4·5%) | 2 (1·3%) | 5 (3·2%) | 20 (2·2%) |
